The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The importance of personalized pain plans for patients with SCD
Wally Smith, MD, Virginia Commonwealth University, Richmond, VA, briefly discusses the need for implementing personalized pain plans for patients with sickle cell disease (SCD) to ensure that care is individualized and that each patient is included in the decision-making process when selecting a pain management strategy. Prof. Smith highlights that clinicians are not adequately communicating with patients to ensure their personal wishes are heard. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Pfizer, Agios; DSMB: Novo Nordisk, Novartis.
